169 related articles for article (PubMed ID: 24627909)
21. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.
Estey EH
Leukemia; 2013 Sep; 27(9):1803-12. PubMed ID: 23757301
[TBL] [Abstract][Full Text] [Related]
22. DNA hypomethylation-mediated overexpression of carbonic anhydrase 9 induces an aggressive phenotype in ovarian cancer cells.
Sung HY; Ju W; Ahn JH
Yonsei Med J; 2014 Nov; 55(6):1656-63. PubMed ID: 25323905
[TBL] [Abstract][Full Text] [Related]
23. Epigenetic drug discovery: targeting DNA methyltransferases.
Foulks JM; Parnell KM; Nix RN; Chau S; Swierczek K; Saunders M; Wright K; Hendrickson TF; Ho KK; McCullar MV; Kanner SB
J Biomol Screen; 2012 Jan; 17(1):2-17. PubMed ID: 21965114
[TBL] [Abstract][Full Text] [Related]
24. Trials show delayed recurrence in ovarian cancer.
Bender E
Cancer Discov; 2013 Jun; 3(6):OF8. PubMed ID: 23749546
[TBL] [Abstract][Full Text] [Related]
25. Primary Immunoprevention of Epithelial Ovarian Carcinoma by Vaccination against the Extracellular Domain of Anti-Müllerian Hormone Receptor II.
Mazumder S; Johnson JM; Swank V; Dvorina N; Martelli E; Ko J; Tuohy VK
Cancer Prev Res (Phila); 2017 Nov; 10(11):612-624. PubMed ID: 29093011
[TBL] [Abstract][Full Text] [Related]
26. Change in gene expression profiles of secreted frizzled-related proteins (SFRPs) by sodium butyrate in gastric cancers: induction of promoter demethylation and histone modification causing inhibition of Wnt signaling.
Shin H; Kim JH; Lee YS; Lee YC
Int J Oncol; 2012 May; 40(5):1533-42. PubMed ID: 22246241
[TBL] [Abstract][Full Text] [Related]
27. Cancer-germline antigen vaccines and epigenetic enhancers: future strategies for cancer treatment.
Gjerstorff MF; Burns J; Ditzel HJ
Expert Opin Biol Ther; 2010 Jul; 10(7):1061-75. PubMed ID: 20420535
[TBL] [Abstract][Full Text] [Related]
28. Effect of Combined Epigenetic Treatments and Ectopic NIS Expression on Undifferentiated Thyroid Cancer Cells.
Massimino M; Tirrò E; Stella S; Frasca F; Vella V; Sciacca L; Pennisi MS; Vitale SR; Puma A; Romano C; Manzella L
Anticancer Res; 2018 Dec; 38(12):6653-6662. PubMed ID: 30504373
[TBL] [Abstract][Full Text] [Related]
29. DSS1 promoter hypomethylation and overexpression predict poor prognosis in melanoma and squamous cell carcinoma patients.
Venza M; Visalli M; Catalano T; Beninati C; Teti D; Venza I
Hum Pathol; 2017 Feb; 60():137-146. PubMed ID: 27825810
[TBL] [Abstract][Full Text] [Related]
30. Expression and epigenetic regulation of angiogenesis-related factors during dormancy and recurrent growth of ovarian carcinoma.
Lyu T; Jia N; Wang J; Yan X; Yu Y; Lu Z; Bast RC; Hua K; Feng W
Epigenetics; 2013 Dec; 8(12):1330-46. PubMed ID: 24135786
[TBL] [Abstract][Full Text] [Related]
31. Decitabine: development of a DNA methyltransferase inhibitor for hematological malignancies.
Lyons J; Bayar E; Fine G; McCullar M; Rolens R; Rubinfeld J; Rosenfeld C
Curr Opin Investig Drugs; 2003 Dec; 4(12):1442-50. PubMed ID: 14763130
[TBL] [Abstract][Full Text] [Related]
32. Epigenetic biomarkers in epithelial ovarian cancer.
Gloss BS; Samimi G
Cancer Lett; 2014 Jan; 342(2):257-63. PubMed ID: 22245949
[TBL] [Abstract][Full Text] [Related]
33. Decitabine and Cedazuridine.
Am J Health Syst Pharm; 2020 Oct; 77(22):1809-1811. PubMed ID: 32945859
[No Abstract] [Full Text] [Related]
34. Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition.
Fejzo MS; Chen HW; Anderson L; McDermott MS; Karlan B; Konecny GE; Slamon DJ
Gynecol Oncol; 2021 Feb; 160(2):539-546. PubMed ID: 33229045
[TBL] [Abstract][Full Text] [Related]
35. DNA methylation and gene silencing in cancer.
Baylin SB
Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S4-11. PubMed ID: 16341240
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic silencing of the LDOC1 tumor suppressor gene in ovarian cancer cells.
Buchholtz ML; Brüning A; Mylonas I; Jückstock J
Arch Gynecol Obstet; 2014 Jul; 290(1):149-54. PubMed ID: 24554348
[TBL] [Abstract][Full Text] [Related]
37. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
38. Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer.
Khan AN; Kolomeyevskaya N; Singel KL; Grimm MJ; Moysich KB; Daudi S; Grzankowski KS; Lele S; Ylagan L; Webster GA; Abrams SI; Odunsi K; Segal BH
Oncotarget; 2015 May; 6(13):11310-26. PubMed ID: 25888637
[TBL] [Abstract][Full Text] [Related]
39. Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells.
Heller G; Schmidt WM; Ziegler B; Holzer S; Müllauer L; Bilban M; Zielinski CC; Drach J; Zöchbauer-Müller S
Cancer Res; 2008 Jan; 68(1):44-54. PubMed ID: 18172295
[TBL] [Abstract][Full Text] [Related]
40. DNA methylation and cancer.
Gokul G; Khosla S
Subcell Biochem; 2013; 61():597-625. PubMed ID: 23150269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
